Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

• Published in: Journal of Global Antimicrobial Resistance Vol. 33; pp. 321 - 327
• Main Authors: Oliva, A., Al Ismail, D., Arcari, G., Miele, MC, Casali, E., Sacco, F., Volpicelli, L., De Angelis, M., Mascellino, M.T., Cancelli, F., Raponi, G., Carattoli, A., Venditti, M
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2023; Elsevier
• Subjects: Agar - therapeutic use; Carbapenems; Ceftazidime - therapeutic use; Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae KPC-variant; Fosfomycin; Fosfomycin - pharmacology; Fosfomycin - therapeutic use; Humans; Infectious Disease; Klebsiella Infections - drug therapy; Klebsiella pneumoniae; Meropenem - pharmacology; Meropenem - therapeutic use; Meropenem/vaborbactam; Synergism; Meropenem/vaborbactam; Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae KPC-variant; Carbapenems; Synergism; Fosfomycin

•Clinical characteristics and fosfomycin synergism of KPC-variants were investigated.•KPC-variant detection follows a previous CZA-susceptible KPC-Kp in the same patient.•Treatment with meropenem achieved clinical cure in all the patients.•Fosfomycin plus meropenem resulted in full synergism in 40%...